胃泌素释放肽前体在小细胞肺癌诊断及治疗中应用探讨

Application of Gastrin-releasing Peptide Precursors in the Diagnosis and Treatment of Small Cell Lung Cancer

目的:探究胃泌素释放肽前体在小细胞肺癌诊断及治疗中应用。方法:选取2018年12月~2019年11月某院收治的小细胞肺癌和非小细胞肺癌患者各65例,分为小细胞肺癌患者组和非小细胞肺癌患者组。结果:小细胞肺癌组的ProGRP(胃泌素释放肽前体)、CEA(癌胚抗原)以及NSE(神经元特异度烯醇化酶)等血清指标高于非小细胞肺癌组(P<0.05),且小细胞肺癌组的CYFRA21-1(细胞角蛋白片段浓度)等血清指标明显低于非小细胞肺癌组(P<0.05);小细胞肺癌组中,ProGRP的敏感度和特异度均高于CEA、NSE和CYFRA21-1等血清指标(P<0.05)。结论:ProGRP可以为小细胞肺癌的临床诊断和治疗提供依据,值得推广。

Objective:To explore the application of gastrin-releasing peptide precursors in the diagnosis and treatment of small cell lung cancer.Methods:65 patients with small cell lung cancer and non-small cell lung cancer admitted to a hospital from December 2018 to November 2019 were selected and divided into small cell lung cancer group and non-small cell lung cancer group.Results:The serum indexes such as ProGRP(gastrin-releasing peptide precursor),CEA(carcinoembryonic antigen),and NSE,neurons enolization enzymes)in the small cell lung cancer group were higher than those in non-small cell lung cancer group(P<0.05),and the serum index such as CYFRA21-1(cell keratin fragments concentration)in the small cell lung cancer group was lower than that in the non-small cell lung cancer group(P<0.05).In the small cell lung cancer group,the sensitivity and specificity of ProGRP were higher than those of CEA,NSE and CYFRA21-1(P<0.05).Conclusion:ProGRP can provide basis for the clinical diagnosis and treatment of small cell lung cancer,and it is worthy of promotion.